Drug intelligence / Profile preview

BMS-986242 + nivolumab

Development stage: Discontinued
Lead developer: Bristol Myers Squibb
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Oral, Intravenous

Overview

BMS-986242 + nivolumab is a **combination therapy** consisting of BMS-986242, an **oral small molecule inhibitor of indoleamine 2,3-dioxygenase 1 (IDO1)**, and **nivolumab (Opdivo)**, a **monoclonal antibody targeting programmed death-1 (PD-1)**. BMS-986242 was designed for cancer immunotherapy, aiming to inhibit the immunosuppressive enzyme IDO1, which is implicated in tumor immune escape by catalyzing the conversion of tryptophan to kynurenine. Nivolumab blocks the PD-1 checkpoint on T cells, enhancing anti-tumor immune responses. This combination was investigated by Bristol Myers Squibb in clinical trials for various advanced cancers, hypothesizing synergistic effects by simultaneously overcoming two immune resistance mechanisms[1][3].

Other names: BMS-986242 + OpdivoBMS-986242 + BMS-936558

Targets

IDO1 (Indoleamine 2,3-dioxygenase 1)PDCD1 (Programmed cell death protein 1 receptor)

Beyond the preview

Go deeper on BMS-986242 + nivolumab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BMS-986242 + nivolumab.

Explore the full profile